Pennsylvania is currently home to 3293 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Sleep Promotion Program Primary Care
NCT06240325
Recruiting
Investigators developed a brief, scalable, behavioral Sleep Promotion Program (SPP) for adolescents with short sleep duration and sleep-wake irregularity, which relies on two individual sessions and smart phone technology to deliver evidence-based strategies. This R34 will test the feasibility and initial effectiveness of the SPP program and provider training via pilot randomized controlled trial (RCT, n=50) comparing SPP to Sleep Psychoeducation, a brief session on healthy sleep habits. Partici... Read More
Gender:
ALL
Ages:
Between 12 years and 18 years
Trial Updated:
02/03/2025
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Sleep, Sleep Disturbance, Insufficient Sleep
Register for Updates
SELUTION 4 De Novo Small Vessel IDE Trial
NCT05946629
Recruiting
Prospective, randomized controlled, single-blind, multicenter, clinical trial to demonstrate the safety and efficacy of the SELUTION SLR 014 PTCA DEB for treatment of de novo lesions in small coronary vessels, defined as reference vessel diameter (RVD) of 2.00 mm to 2.75 mm, in support of a pre-market approval (PMA) application to the United States (US) FDA. The Study will enroll up to 910 randomized subjects, up to 30 subjects in a parallel angiographic substudy, and up to 20 subjects in a par... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: UPMC Pinnacle, Mechanicsburg, Pennsylvania
Conditions: Coronary Artery Disease
Register for Updates
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815
NCT05557045
Recruiting
This phase 1 study will investigate the safety, dosing, and initial antitumor activity of JZP815 in participants with advanced or metastatic solid tumors harboring alterations in the MAPK pathway.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania
Conditions: Advanced Cancer, Metastatic Cancer, Solid Tumor
Register for Updates
Auriculo-Nerve Stimulation on Post-Operative Opioid Requirement
NCT05506878
Recruiting
The NSS-2 BRIDGE® device (NSS stands for Neuro-Stimulation System) is a disposable device that stimulates the branches of cranial nerves and of the superficial cervical plexus innervating the ear. Because the stimulation of the nerves of the ear by the NSS-2 BRIDGE® device (NBD®) has been shown to modulate pain pathways in rodents, decrease abdominal pain in adolescents with inflammatory bile syndrome and due to the results of our preliminary pilot study, the investigators hypothesized that this... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: University of Pittsburgh Medical Center - Magee-Womens Hospital, Pittsburgh, Pennsylvania
Conditions: Opioid Use, Auriculotherapy, Pain, Abdominal, Cancer Pain, Liver Transplant
Register for Updates
PET Image in PAH Patients
NCT05452889
Recruiting
Pulmonary arterial hypertension (PAH) is mortal disease affecting the blood vessels of the lung. Despite its morbid prognosis, PAH is often misdiagnosed or ignored, with an average time of 44 months between onset of symptoms to diagnosis and substantial progression of disease severity. Therefore, a pressing need exists to develop non-invasive diagnostic imaging tools, particularly that can detect early disease stages. Efforts have been made to develop such imaging capabilities through platform... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/03/2025
Locations: Montefiore Hospital Clinical and Translational Research Center, Pittsburgh, Pennsylvania
Conditions: Pulmonary Arterial Hypertension
Register for Updates
Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
NCT05074810
Recruiting
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with sotorasib with or without defactinib in patients with KRAS G12C Non-Small Cell Lung Cancer (NSCLC) in patients who have been exposed to prior G12C inhibitor and those who have not been exposed to prior G12C inhibitor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Consultants in Medical Oncology & Hematology, Broomall, Pennsylvania
Conditions: Non Small Cell Lung Cancer, KRAS Activating Mutation
Register for Updates
Clinical and Radiographic Success of MTA vs Biodentine
NCT04863222
Recruiting
The purpose of this prospective study is to compare the clinical and radiographic success of MTA and Biodentine as a medicament in vital pulp therapy in maxillary and mandibular primary molars in a pediatric population. There is limited research currently on Biodentine since it's a novel product. Biodentine is less expensive than MTA and does not cause discoloration like MTA. Biodentine may be an alternative medicament used for vital pulp therapy in primary molars.
Gender:
ALL
Ages:
Between 2 years and 12 years
Trial Updated:
02/03/2025
Locations: Geisinger, Danville, Pennsylvania
Conditions: Indirect Pulp Cap, Pulpotomy
Register for Updates
BI-1808 As a Single Agent and with Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
NCT04752826
Recruiting
The goal of this first in human clinical trial is to test BI-1808 administered as single agent and in combination with pembrolizumab in subjects with advanced malignancies whose disease has progressed after standard therapy. The main questions it aims to answer are: * how safe and tolerable is BI-1808 * what is maximum tolerated or administrated dose * to determine recommended dose for further clinical trials. Participants will receive infusions of BI-1808 alone or combination with pembrolizum... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Advanced Malignancies, Ovarian Cancer, T-cell Lymphoma, Melanoma
Register for Updates
Studying How Outpatient Water AffEcts Risks with Drains (SHOWER Study)
NCT04725916
Recruiting
This is a prospective randomized, controlled, unblinded, interventional feasibility study to evaluate if showering with post operative drains in place leads to an increase in complications. The patients included in the study will be those undergoing breast reductions and panniculectomies at Geisinger Medical Center. The patients will be randomized post operatively into one of two groups: 1) patients instructed to shower with drains in place, and 2) patients instructed not to shower while they ha... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Geisinger Health, Danville, Pennsylvania
Conditions: Postoperative Wound Infection, Postoperative Complications, Surgical Site Infection, Drain Site Complication
Register for Updates
Electrographic Seizure Management and Neurobehavioral Outcomes in Critically Ill Children
NCT03419260
Recruiting
Electrographic seizures are common in critically ill patients leading to increased use of resource-intense continuous EEG monitoring for seizure identification and management. When identified, electrographic seizures are generally treated with anti-seizure medications, but there are very limited data available regarding optimal treatment in terms of the efficacy or safety of specific anti-seizure medications or overall management strategies. This is a single-center prospective observational stu... Read More
Gender:
ALL
Ages:
Between 1 month and 18 years
Trial Updated:
02/03/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Seizures
Register for Updates
Expanded Access Protocol Using CD3+/CD19+ Depleted PBSC
NCT02356653
Recruiting
The goal of this protocol is to expand access for patients who lack a fully HLA (Human leukocyte antigen) matched sibling donor and who are candidates for allogeneic hematopoietic stem cell transplant (HSCT). These patients have a serious or immediately life-threatening disease for which HSCT is indicated. These patients are not eligible for other Children's Hospital of Philadelphia IRB approved protocols that utilize CliniMACs technology for T depletion.
Gender:
ALL
Ages:
30 years and below
Trial Updated:
02/03/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Leukemia, Inborn Errors of Metabolism, Bone Marrow Failure Syndromes, Immunodeficiencies, Immunodysregulation Polyendocrinopathy Enteropathy X-linked Syndrome
Register for Updates
Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients with Chronic Spontaneous Urticaria (CSU)
NCT06162728
Recruiting
This trial will be performed as a three-part dose escalating clinical trial where Parts 1 is open label and Parts 2 and 3 are randomized, double-blinded, and placebo-controlled. The trial is intended to determine the safety and tolerability and assess the preliminary efficacy of briquilimab in adult participants with chronic spontaneous urticaria (CSU), who remain symptomatic despite treatment with H1 antihistamines and omalizumab. Additionally, pharmacokinetic (PK) properties of briquilimab, a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2025
Locations: Site 114, Philadelphia, Pennsylvania
Conditions: Chronic Spontaneous Urticaria
Register for Updates